Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AI042401-03
Application #
2887666
Study Section
Special Emphasis Panel (ZRG5-BM-2 (04))
Program Officer
Dixon (Dmid), Dennis M
Project Start
1997-05-01
Project End
2002-04-30
Budget Start
1999-05-01
Budget End
2000-04-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Thomas, Derek P; Viudes, Angel; Monteagudo, Carlos et al. (2006) A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. Proteomics 6:6033-41
Monteagudo, C; Viudes, A; Lazzell, A et al. (2004) Tissue invasiveness and non-acidic pH in human candidiasis correlate with ""in vivo"" expression by Candida albicans of the carbohydrate epitope recognised by new monoclonal antibody 1H4. J Clin Pathol 57:598-603
Viudes, Angel; Lazzell, Anna; Perea, Sofia et al. (2004) The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis. FEMS Microbiol Lett 232:133-8
Perea, Sofia; Lopez-Ribot, Jose L; Wickes, Brian L et al. (2002) Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 46:1695-703
Martinez, M; Lopez-Ribot, J L; Kirkpatrick, W R et al. (2002) Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother 49:515-24
Viudes, A; Peman, J; Canton, E et al. (2002) Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21:767-74
Viudes, A; Peman, J; Canton, E et al. (2002) Two cases of fungemia due to Candida lusitaniae and a literature review. Eur J Clin Microbiol Infect Dis 21:294-9
Martinez, Marcos; Lopez-Ribot, Jose L; Kirkpatrick, William R et al. (2002) Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol 40:3135-9
Viudes, A; Perea, S; Lopez-Ribot, J L (2001) Identification of continuous B-cell epitopes on the protein moiety of the 58-kiloDalton cell wall mannoprotein of Candida albicans belonging to a family of immunodominant fungal antigens. Infect Immun 69:2909-19
Perea, S; Lopez-Ribot, J L; Kirkpatrick, W R et al. (2001) Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45:2676-84

Showing the most recent 10 out of 20 publications